AMRI Extends Long Term Supply Relationship with GE Healthcare

        AMRI Extends Long Term Supply Relationship with GE Healthcare

  PR Newswire

  ALBANY, New York, Dec. 6, 2012

-- Demonstrates AMRI's Commitment to Performance, Quality and Customer

ALBANY, New York, Dec. 6, 2012 /PRNewswire/ --AMRI (Nasdaq: AMRI) today
announced the extension of a commercial supply relationship with GE Healthcare
(NYSE: GE) for Aminobisamide Hydrochloride (ABA). Under the terms of the
agreement, AMRI will supply ABA, an intermediate material used in diagnostic
imaging agents. This substantial contract commitment positions AMRI as a
strategic supplier to GE Healthcare.

(Logo: )

Production will continue at AMRI's large scale manufacturing subsidiary
located in Rensselaer, N.Y. The new contract extends through December 31,
2016, and replaces the existing supply contract between GE and AMRI that has
been in effect since 2005.

"We are pleased to once again extend our long-term relationship with GE
Healthcare," said AMRI Chairman, CEO and President Thomas E. D'Ambra, Ph.D.
"The renewal of this relationship underscores the confidence that premier
global pharmaceutical and health care companies have in AMRI's ability to meet
their critical product needs."

Dr. D'Ambra continued, "The ABA product relationship with GE Healthcare has
been an important one for AMRI since acquisition of the Rensselaer plant in
2003 and at this time is our largest commercial supply arrangement. We
continue to be pleased with the progress that we are making in our Large Scale
Manufacturing business segment, the largest component of which is our
Rensselaer site. We are adding new customers and new products at this
facility, along with continuing the long term relationships, like GE
Healthcare, that have formed the basis of our revenue stream. The extension of
this key, long term agreement provides a consistent and high quality revenue
source for this business unit through 2016."

About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully integrated
drug discovery, development, and manufacturing services. For over 21 years
AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further

AMRI Rensselaer AMRI's 23-acre Rensselaer site is located in New York State
and provides contract cGMP manufacturing of bulk active pharmaceuticals and
advanced intermediates for clinical phase scale-up requirements up to and
including full scale commercial manufacturing. The facility, which hosts over
35 customer audits each year, maintains an excellent U.S. Federal Drug
Administration (FDA) quality inspection record and is fully licensed by the
U.S. Drug Enforcement Administration (DEA) to produce Schedule I, II, III, IV
and V controlled substances. The site, which received its SafeBridge Potent
Compound Safety Certification in 2010, has a state-of-art high-potency
compound production facility that can handle quantities from grams to 120 kgs.
Combining a scientifically strong staff with our highly experienced workforce
allows the Rensselaer site to deliver its best to our customers. Currently, 26
Commercial Products are routinely manufactured from 25 kg individual batches
to 7 metric ton annual campaigns.

Contacts Investors – Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261Media – Gina Monari, AMRI Communications, +1-518-512-2512

Press spacebar to pause and continue. Press esc to stop.